Search

Author/Creator Humphrey, K.

1. Demonstration of laser pulse amplification by stimulated Brillouin scattering. (1st September 2014)

Authors:
Guillaume, E.; Humphrey, K.; Nakamura, H.; Trines, R. M. G. M.; Heathcote, R.; Galimberti, M.; Amano, Y.; Doria, D.; Hicks, G.; Higson, E.; Kar, S.; Sarri, G.; Skramic, M.; Swain, J.; Tang, K.; Weston, J.; Zak, P.; Alves, E. P.; Fonseca, R. A.; Fiúza, F.
Journal:
High power laser science and engineering
Issue:
Volume 2 (2014)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Demonstration of laser pulse amplification by stimulated Brillouin scattering. (1st September 2014)

Authors:
Guillaume, E.; Humphrey, K.; Nakamura, H.; Trines, R. M. G. M.; Heathcote, R.; Galimberti, M.; Amano, Y.; Doria, D.; Hicks, G.; Higson, E.; Kar, S.; Sarri, G.; Skramic, M.; Swain, J.; Tang, K.; Weston, J.; Zak, P.; Alves, E. P.; Fonseca, R. A.; Fiúza, F.
Journal:
High power laser science and engineering
Issue:
Volume 2 (2014)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019)

Authors:
Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
82
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. (12th June 2019)

Authors:
Tausch, E.; Bahlo, J.; Robrecht, S.; Schneider, C.; Bloehdorn, J.; Schrell, S.; Galler, C.; Al‐Sawaf, O.; Fink, A.; Eichhorst, B.; Kreuzer, K.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Döhner, H.; Fischer, K.; Hallek, M.; Stilgenbauer, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
84
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. (12th June 2019)

Authors:
Al‐Sawaf, O.; Lilienweiss, E.; Bahlo, J.; Robrecht, S.; Fink, A.; Patz, M.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Ritgen, M.; Tausch, E.; Stilgenbauer, S.; Eichhorst, B.; Fischer, K.; Hallek, M.; Kreuzer, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
104
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY. (12th June 2019)

Authors:
Wu, J.; Bolen, C.; Seymour, J.F.; Hillmen, P.; Eichhorst, B.; Eldering, E.; Kipps, T.J.; Langerak, A.W.; Mellink, C.; van der Kevie‐Kersemaekers, A.F.; Owen, C.; Chyla, B.; Punnoose, E.A.; Wang, J.; Boyer, M.; Humphrey, K.; Jiang, Y.; Kater, A.P.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
106
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY. (12th June 2019)

Authors:
Morschhauser, F.; Flinn, I.W.; Gasiorowski, R.; Illés, Á.; Feugier, P.; Greil, R.; Johnson, N.A.; Larouche, J.; Lugtenburg, P.J.; Patti, C.; Salles, G.; Trněný, M.; de Vos, S.; Mir, F.; Kornacker, M.; Punnoose, E.A.; Samineni, D.; Szafer‐Glusman, E.; Petrich, A.; Sinha, A.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). (23rd June 2022)

Authors:
Piccione, E. C.; Belousov, A.; Hamidi, H.; Carlo-Stella, C.; Dickinson, M.; Morschhauser, F.; Lundberg, L.; Humphrey, K.; Tracy, S.; Hutchings, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1096
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS. (23rd June 2022)

Authors:
Dickinson, M.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Wróbel, T.; Offner, F.; Trněný, M.; Wu, S.-J.; Cartron, G.; Hertzberg, M.; Sureda, A.; Perez-Callejo, D.; Lundberg, L.; Relf, J.; Clark, E.; Humphrey, K.; Hutchings, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
121
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗